TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05134662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study: NCT04804774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW program modified for people with Type 2 diabetes
Description: This 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and private online community. The program involves: self-monitoring of weight, dietary intake, and physical activity; dietary changes; increasing physical activity; shift in mindset; and behavioral strategies to manage goals. Participants will set goals and weigh-in with a coach via virtual workshop weekly and be encouraged to use the app and private online community daily. The virtual workshop features a behavior change technique and enables the participant to practice it to support their goals. Participants are given a personalized food plan based on expert healthy eating guidelines, an activity plan to promote regular physical activity and techniques to help shift mindset for lasting change. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals weekly. Participants will be encouraged to participate in a private Facebook group for motivational support.
Study: NCT05564741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 1 MG/ML
Description: As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine 1 MG/ML
Description: As proxy for hypotension we record amount of Norepinephrine given during the study time of 30 minutes
Study: NCT05481216

Intervention type: OTHER
Intervention: COVID-19
Description: Diagnosed with COVID-19 infection

Intervention type: OTHER
Intervention: COVID-19
Description: Diagnosed with COVID-19 infection

Intervention type: OTHER
Intervention: HIV-1 infection
Description: Diagnosed with HIV-1 infection

Intervention type: OTHER
Intervention: HIV-1 infection
Description: Diagnosed with HIV-1 infection
Study: NCT06383702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin sustained-release tablets
Description: Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Study: NCT06061432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic restoration of gastrointestinal continuity after Hartmann procedure
Description: EndoHARP is a new technique proposed to restore gastrointestinal continuity after the Hartmann's procedure. For EndoHARP, a fixed loop of the large intestine will be identified on endosonography after an echoendoscope is inserted into the rectal stump under endoscopic guidance. Then, using the set for inserting self-expandable metal transmural endoprosthesis (20 mm in diameter and 10 mm in length) with electrocautery (as in endoscopic gastroenterostomy), EUS-guided anastomosis of the rectal stump to the large intestine loop will be performed, allowing the natural passage of intestinal contents through the endoscopic anastomosis, restoring gastrointestinal continuity. The aim of leaving the self-expandable transmural endoprosthesis in the anastomosis is not only to maintain the patency of the intestinal anastomosis of at least 20 mm in diameter, but also to diminish the risk of endoscopic intestinal anastomotic leak by completely covering the prosthesis with a polymer layer.
Study: NCT06134323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medication-combined transcutaneous vagus nerve stimulation
Description: Two electrodes will be applied 2 cm below the left carotid sinus for active stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: medication-combined sham stimulation
Description: Two electrodes will be applied 2 cm below the left carotid sinus for sham stimulation
Study: NCT05590546

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, only performing cross-sectional analysis of pooled data collected in previous studies

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, only performing cross-sectional analysis of pooled data collected in previous studies
Study: NCT06134804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC9V
Description: ExPEC9V will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC9V
Description: ExPEC9V will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD quadrivalent influenza vaccine
Description: HD quadrivalent influenza vaccine will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD quadrivalent influenza vaccine
Description: HD quadrivalent influenza vaccine will be administered as IM injection.
Study: NCT05335109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Xenon is injected into the body by inhalation in the form of xenon-oxygen mixtures, in which the concentration of xenon is 30%, and oxygen is 30%.~Xenon inhalation is carried out for 30 min daily for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen 30 %
Description: Oxygen-air mixture is injected into the body by inhalation. The oxygen concentration is 30%.~Inhalation of oxygen-air mixture is carried out for 30 min daily for 3 days
Study: NCT05845476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient SOGI Self-Report
Description: EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOGI Resource for Clinical Care Education (SORCE)
Description: SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Center Care Environment
Description: At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
Study: NCT05633407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive a matching placebo during weekly infusions during a treatment period of 24 weeks.~Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Study: NCT06293300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT A
Description: Participants with TBI-associated photophobia will come one time in person to the clinic and receive 35 Units of BoNT-A injected in 7 forehead sites (0.1 cc in each location).
Study: NCT04244214

Intervention type: OTHER
Intervention: More Stamina
Description: More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
Study: NCT04774419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
Study: NCT05015998

Intervention type: OTHER
Intervention: Non-interventional
Description: Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
Study: NCT05481125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon IOL
Description: Alcon Clareon Aspheric Hydrophobic Acrylic IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
Study: NCT04869449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg (two 200 mg tablets) orally
Study: NCT06212466

Intervention type: DEVICE
Intervention: CardioFlux
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.

Intervention type: DEVICE
Intervention: CardioFlux
Description: The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.
Study: NCT05012371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06454721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-DFO-BIIB080
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB080
Description: Administered as specified in the treatment arm.
Study: NCT05155709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siremadlin
Description: Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siremadlin
Description: Siremadlin is a capsule taken orally once a day (QD) and comes in 10 mg, 20 mg and 30 mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Venetoclax is a tablet taken orally once a day (QD) and comes in 10 mg, 50 mg and 100 mg strengths.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacitidine is a powder for suspension for injection or powder for solution for infusion taken intravenously or subcutaneously according to standard local clinical practice
Study: NCT05649306

Intervention type: OTHER
Intervention: Additional Education
Description: Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services

Intervention type: OTHER
Intervention: Additional Education
Description: Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services

Intervention type: OTHER
Intervention: Questionnaires
Description: Female Sexual Function Index, Demoralization Scale-II

Intervention type: OTHER
Intervention: Questionnaires
Description: Female Sexual Function Index, Demoralization Scale-II

Intervention type: OTHER
Intervention: Attendance Diary
Description: Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized

Intervention type: OTHER
Intervention: Attendance Diary
Description: Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
Study: NCT05917977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective Motivational Interviewing plus Education Materials
Description: The participants in the intervention group will receive IGD educational materials as well as four counseling sessions of CMI intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group (Education Materials)
Description: The participants in the control group will receive IGD educational materials.
Study: NCT05481125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Toric IOL
Description: Clareon Toric Aspheric Hydrophobic Acrylic Toric IOL for the visual correction of aphakia with pre-existing corneal astigmatism in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance IOL
Description: TECNIS Eyhance IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyhance Toric IOL
Description: TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Description: Cataract removal by routine small incision phacoemulsification surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification surgery
Description: Cataract removal by routine small incision phacoemulsification surgery
Study: NCT05379270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet soda
Description: Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
Study: NCT05353348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose, recombinant human erythropoietin, ascorbic acid
Description: During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team
Study: NCT06422455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive provider-based genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive genetics education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive provider-based genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05996328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-delivered meals and short-term dietary counseling
Description: Home-delivered, low-sodium, nutritionally robust meals for 6 weeks plus two additional remotely delivered dietary counseling sessions in addition to the study-defined standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study -defined standard of care
Description: study-defined standard of care consists of standardized dietary education and a single dietary counseling session shortly after discharge
Study: NCT04990141

Intervention type: PROCEDURE
Intervention: Peripheral blood collection in cases group
Description: Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group

Intervention type: PROCEDURE
Intervention: Peripheral blood collection in control group
Description: Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
Study: NCT05869682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Wear AYOpro BWL therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Wear AYOpro BWL therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Drug Therapy
Description: Receive SOC ADT combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Drug Therapy
Description: Receive SOC ADT combination therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05763784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tightrope
Description: Tightrope use special fiber and a set of metal buttons to fix diastasis of a joint.
Study: NCT04686162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bae application
Description: Patients will be assisted by a research team member to install and configure the application bae on their smartphone; then, they will be trained to use it.~Bae proposes 4 types of assessments :~1. 5 times a day during 3 days, every month (5 minutes) : patients can assess their emotions, their thoughts, their behavior and their occurrence context.~2. Weekly (7 minutes) : consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends), and their quality of life.~3. Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.~4. Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help.~They can contact a relative or call the psychiatric emergency service directly by clicking on a button.~Patients can try to identify their own warning signs, to prevent suicidal behavior.